Business Parks & Science Centres



Picture Kentro Design Corporate and Web Design Berlin 600x60px
Collaboration › Details

Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019


Period Period 2019-01-09
Organisations Partner, 1st Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
  Partner, 2nd J.P. Morgan Securities LLC
Products Product J.P. Morgan 37th Annual Healthcare Conference 2019 San Francisco
  Product 2 drug discovery services
Persons Person van de Stolpe, Onno (Galapagos 1999– CEO + Founder before IntroGene BV + Molecular Probes Europe BV)
  Person 2 Goodwin, Elizabeth (Galapagos 201112 Director Investor Relations)

Galapagos N.V.. (12/21/18). "Press Release: Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference". Mechelen.

Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.

Onno van de Stolpe, CEO, will present on Wednesday, January 9 at 20:30 CET (11:30 a.m. Pacific time). The presentation will be live audio webcast and can be accessed via the following link: A replay of the webcast will be available for 90 days on the Galapagos' website at

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at glpg


Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784

Sofie Van Gijsel
Director IR
+32 485 19 14 15


Evelyn Fox
Director Communications
+31 6 53 591 999

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Record changed: 2019-03-14


Picture [LSE] – The Business Web Portal 600x60px

More documents for Galapagos (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top